Human Gut Microbiota and Intestinal Mucosa

The human gut microbiota and intestinal mucosa constitute a complex symbiotic ecosystem essential for host homeostasis, comprising trillions of bacteria, fungi, and viruses interacting with the intestinal epithelium and underlying immune cells (NIH, 2023). This system performs vital biological functions, including the fermentation of non-digestible carbohydrates into short-chain fatty acids, synthesis of vitamins K and B12, and the development of the gut-associated lymphoid tissue (Belkaid & Hand, 2014). Disruptions in the composition of the microbiota or the integrity of the mucosal barrier, known as dysbiosis and leaky gut respectively, are implicated in a wide range of diseases such as inflammatory bowel disease (IBD), obesity, and Clostridioides difficile infection (Vancamelbeke & Vermeire, 2017). Pharmacological interventions targeting this system include antibiotics, probiotics, and novel live biotherapeutic products like fecal microbiota transplantation (FMT) derivatives (FDA, 2023). These therapies aim to restore microbial diversity, suppress pathogens, and enhance the protective function of the intestinal lining to treat both local and systemic conditions. Understanding the cross-talk between microbial metabolites and host receptors is a major focus of modern drug discovery (StatPearls, 2023).

Other names

Gut microbiomeIntestinal floraGastrointestinal microbiotaIntestinal mucosal barrierGut-associated lymphoid tissue (GALT) environment

Therapeutic interventions modulate the gut environment through the restoration of microbial diversity, competitive exclusion of pathogenic species, production of antimicrobial peptides, and the reinforcement of the mucosal epithelial barrier to prevent systemic translocation of endotoxins (NIH, 2023; Belkaid & Hand, 2014).